FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kusserow Paul B. K. 		2. Issuer Name and Ticker or Trading Symbol

AMEDISYS INC [ AMED ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CEO and President
(Last)          (First)          (Middle)

3854 AMERICAN WAY, SUITE A 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/20/2018
(Street)

BATON ROUGE, LA 70816
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/20/2018     M    18750   A $0.00   97401   D    
Common Stock   2/20/2018     F    7393   D $56.87   90008   D    
Common Stock                  452   (1) I   Through 401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance-Based Restricted Shares     (2) 2/20/2018     M         18750      (2)   (2) Common Stock   18750   $0.00   18750   (2) D    
Stock Option (Right to Buy)   $26.78   2/20/2018     A      62500       2/20/2018   3/31/2025   Common Stock   62500   $0.00   187500   (3) D    

Explanation of Responses:
(1)  The information in this report is based on a plan statement dated as of December 31, 2017.
(2)  Each performance-based restricted share represents a contingent right to receive one share of unrestricted common stock. The performance-based restricted shares shall vest, if at all, based on the certification by the Comensation Committee of the Issuer's Board of Directors of the achievement of identified performance goals for fiscal years 2015 through 2018, respectively (subject to certain pro-rated vesting provisions as provided in the award agreement for the performance-based restricted shares). The performance criteria for fiscal year 2017 were met. The number of performance-based restricted shares listed in Table II, Column 9 represents the maximum number of shares of unrestricted common stock the Reporting Person would receive based on the satisfaction of all of the remaining pre-determined performance goals.
(3)  On March 31, 2015, the reporting person was granted an option to purchase 250,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2017 were met, resulting in vesting of the option as to 62,500 shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kusserow Paul B. K.
3854 AMERICAN WAY, SUITE A
BATON ROUGE, LA 70816 		X
CEO and President

Signatures
/s/ Jennifer R. Guckert, pursuant to a power of attorney 2/22/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amedisys Charts.
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amedisys Charts.